Search results

At Series D and beyond, median round sizes continued to decline for venture-backed startups in Q1 2023.

For the first time in a year, Series B valuations are trending up.

Healthtech deal count declined in Q4, but deal value showed a slight uptick.

In Q1 2023, fundraising continued to decline at most stages while valuations rebounded at Series A and B. Learn more in our preview report.

Median valuations trended down for startups at every stage in Q4 2022. Here’s what founders need to know about step-up multiples before raising a new round.

Carta data shows median valuations for seed-stage startups were steady in 2022. For SaaS, hardware, healthcare, and fintech, valuations varied.

The global economy took a downward turn in 2022, leaving behind 2021’s environment of easy money and soaring valuations. The U.S. venture capital market followed suit.

What sets a 409A valuation apart from a company valuation for EMI or CSOP? Find the answer in this Carta guide.

Private markets in Q4 2022 continued to see pre-money valuations drop and raising cash became even more difficult. Learn more in our preview report.

Investors continued their retreat from the venture sector in Q3.

In our latest webinar, our in-house experts Triam Zubeldia, UK Valuations Associate, and Jackson O’Brien CFA, US Valuations Manager, came together to discuss HMRC and 409A valuations.